Risks and benefits of early antithrombotic therapy after thrombolytic treatment in patients with acute stroke

Sergio Amaro, Laura Llull, Xabier Urra, Víctor Obach, Álvaro Cervera, Ángel Chamorro, Sergio Amaro, Laura Llull, Xabier Urra, Víctor Obach, Álvaro Cervera, Ángel Chamorro

Abstract

Background: Current guidelines recommend withholding antithrombotic therapy (ATT) for at least 24 h in patients with acute ischemic stroke treated with thrombolytic therapy. Herein, we report a retrospective analysis of a single-centre experience on the safety and efficacy of antithrombotic therapy (ATT) started before or after 24 h of intravenous thrombolysis in a cohort of acute ischemic stroke patients.

Methods: A total of 139 patients (Rapid ATT group) received antithrombotic therapy before 24 h of thrombolysis, and 33 patients (Standard ATT group) after 24 h. The brain parenchyma and vessel status were assessed using simple CT scan on admission, multimodal CT scan at the end of thrombolysis, and angio-CT/MRI scan at day 3. Functional outcome was scored using the modified Rankin Scale (mRS) at day 90.

Results: The two ATT groups had similar demographics, stroke subtypes, baseline NIHSS, thrombolytic strategies, vessel-patency rates at the end of thrombolysis, and incidence of bleeding complications at follow up. At day 3, the Rapid ATT group had a non-significant improved vessel-patency rate than the Standard ATT group. At day 90, a greater proportion of patients in the rapid ATT group had shifted down the mRS, and had improved in the NIHSS score.

Conclusions: ATT initiated before 24 h of intravenous thrombolytic therapy in acute stroke patients disclosed no safety concerns compared with a conventional antithrombotic therapy delay of 24 h and showed better functional outcome at follow up. The value of early initiation of ATT after thrombolysis deserves further assessment in randomized controlled trials.

Conflict of interest statement

Competing Interests: The authors confirm that co-author Dr. A. Chamorro is a PLOS ONE Editorial Board member. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Figures

Figure 1. Modified Rankin Scale score distribution…
Figure 1. Modified Rankin Scale score distribution at day 90 of stroke according to the delay to initiate antithrombotic therapy.
Figure 2. Modified Rankin Scale score distribution…
Figure 2. Modified Rankin Scale score distribution at day 90 of stroke according to presence of patent vessel (TIMI 2–3) or occluded vessel (TIMI 0–1) at day 3.

References

    1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333: 1581–1587.
    1. European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee (2008) Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 25: 457–507.
    1. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, et al. (2007) Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 38: 1655–1711.
    1. Seifried E, Tanswell P, Ellbrück D, Haerer W, Schmidt A (1989) Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. Thromb Haemost 30: 497–501.
    1. Janjua N, Alkawi A, Suri MF, Qureshi AI (2008) Impact of arterial reocclusion and distal fragmentation during thrombolysis among patients with acute ischemic stroke. AJNR Am J Neuroradiol 29: 253–258.
    1. Alexandrov AV, Grotta JC (2002) Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 59: 862–867.
    1. Zinkstok SM, Roos YB, ARTIS investigators (2012) Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet 380: 731–737.
    1. Grond M, Stenzel C, Schmulling S, Rudolf J, Neveling M, et al. (1998) Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 29: 1544–1549.
    1. Schmulling S, Rudolf J, Strotmann-Tack T, Grond M, Schneweis S, et al. (2003) Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke. Cerebrovasc Dis 16: 183–190.
    1. Sanak D, Kuliha M, Herzig R, Roubec M, Skoloudik D, et al. (2012) Prior use of antiplatelet therapy can be associated with a higher chance for early recanalization of the occluded middle cerebral artery in acute stroke patients treated with intravenous thrombolysis. Eur Neurol 67: 52–56.
    1. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, et al. (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24: 35–41.
    1. Abilleira S, Davalos A, Chamorro A, Alvarez-Sabin J, Ribera A, et al. (2011) Outcomes of intravenous thrombolysis after dissemination of the stroke code and designation of new referral hospitals in Catalonia: the Catalan Stroke Code and Thrombolysis (Cat-SCT) Monitored Study. Stroke 42: 2001–2006.
    1. Chamorro A, Vila N, Ascaso C, Blanc R (1999) Heparin in acute stroke with atrial fibrillation: clinical relevance of very early treatment. Arch Neurol 56: 1098–1102.
    1. Chamorro A (2006) Immediate anticoagulation for acute stroke in atrial fibrillation: yes. Stroke 37: 3052–3053.
    1. Lever R, Page CP (2002) Novel drug development opportunities for heparin. Nat Rev Drug Discov 1: 140–148.
    1. Chamorro A, Busse O, Obach V, Toni D, Sandercock P, et al. (2005) The rapid anticoagulation prevents ischemic damage study in acute stroke–final results from the writing committee. Cerebrovasc Dis 19: 402–404.
    1. Phan CM, Yoo AJ, Hirsch JA, Nogueira RG, Gupta R (2012) Differentiation of hemorrhage from iodinated contrast in different intracranial compartments using dual-energy head CT. AJNR Am J Neuroradiol 33: 1088–1094.
    1. Barber PA, Demchuk AM, Zhang J, Bucham AM (2000) Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score [published erratum appears in Lancet 2000; 355: 2170]. Lancet 355: 1670–1674.
    1. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, et al. (1998) Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 352: 1245–1251.
    1. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group (1985) N Engl J Med. 312: 932–936.
    1. Rha JH, Saver JL (2007) The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 38: 967–973.
    1. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial–Italy (MAST-I) Group (1995) Lancet. 346: 1509–1514.
    1. Albers GW, Bates VE, Clark WM, Bell R, Verro P, et al. (2000) Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 283: 1145–1150.
    1. Demchuk AM, Tanne D, Hill MD, Kasner SE, Hanson S, et al. (2001) Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology 57: 474–480.
    1. Molina CA, Alexandrov AV, Demchuk AM, Saqqur M, Uchino K, et al. (2004) Improving the predictive accuracy of recanalization on stroke outcome in patients treated with tissue plasminogen activator. Stroke 35: 151–156.
    1. Cervera A, Justicia C, Reverter JC, Planas AM, Chamorro A (2004) Steady plasma concentration of unfractionated heparin reduces infarct volume and prevents inflammatory damage after transient focal cerebral ischemia in the rat. J Neurosci Res 77: 565–572.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner